Mexico has become the fifth country to approve the authorization of a treatment for Alzheimer's after the United States, Japan, Great Britain, and China. This therapy has been developed by a company based in Indianapolis, Indiana, which has invested 13 billion dollars in research to combat this disease that affects 7.8% of people over 60 years old.
In another aspect, in the fourth quarter of the year, the Southeast Airport Group (ASUR) increased its net profit by 37.2% annually, reaching earnings of 3 billion 589 million pesos. Despite this increase, ASUR has experienced a decrease in passenger traffic at its most important airport, Cancún.
The Mexican Accreditation Entity (EMA), chaired by Raúl Tonel and Cruz, will hold the Standards and Accreditation sessions in Guadalajara, Jalisco. These sessions aim to highlight the importance of compliance with standards and regulations in different states, including Jalisco, Durango, and Yucatán.
In the field of agriculture, the potential of connectivity and digitalization to increase productivity is highlighted. According to the Federal Institute of Telecommunications (IFT), Mexico could achieve a 30% reduction in supplies, a 20% reduction in costs, and a 15% increase in crop yields. Bayer, specialized in health and agriculture, aims to increase agricultural production in Mexico by up to 50% through the use of technologies such as Artificial Intelligence, big data, and IoT.
Although there are challenges such as lack of internet access in some regions and low technology adoption by producers, digitalization of agricultural operations in Mexico is expected to improve significantly in the coming years. Bayer plans to cover 80,000 hectares by 2025, with the expectation of improving yields by 10% during the first months.
Regarding health, the Federal Commission for the Protection against Sanitary Risks (Cofepris) approved a treatment called Donanemab, developed by the pharmaceutical company Lilly, to combat Alzheimer's in Mexico. This breakthrough will benefit a large number of patients, as well as their families and caregivers, providing a new therapeutic alternative in the fight against this disease that affects a large number of people in the country.
